Olema Pharmaceuticals, Inc. (OLMA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
the bull case· 3
185
managers reporting a position in institutional filings indicating broad holder base
13fJun 30 '26+9.33%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '267
disclosed supplier and customer ties in SEC filings showing operational relationships
sec filingsedgarthe bear case· 3
7 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized23
managers whose positions together make up four fifths of the reported value
13fJun 30 '260.32%
of State Street SPDR S&P Biotech ETF's assets the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 10 '26 report. Not a forecast, not advice.
Of the 6 companies Olema Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
OLMA (Olema Pharmaceuticals, Inc.) has 6 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
184 managers report a position worth $1.3B between them, and 23 of them hold 80% of it.
High 9.90 at 2:00 pm ET, low 9.80 at 10:15 am ET.
Olema Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations